

### SECTION 1: IDENTIFICATION

#### 1.1. Product Identifier

**Product Form:** Mixture

**Product Name:** Ceftazidime for Injection, USP

#### 1.2 Recommended Use and Restrictions on Use

**Use of the Substance/Mixture:** Cephalosporin Antibiotic

**Restrictions On Use:** No additional information available

#### 1.3. Name, Address, and Telephone of the Responsible Party

##### Company

WG Critical Care, LLC

120 Route 17 North, Suite 115

Paramus, NJ 07652 USA

+ 1-888-493-0861

[wgccquality@wgcriticalcare.com](mailto:wgccquality@wgcriticalcare.com)

<https://www.wgcriticalcare.com>

#### 1.4. Emergency Telephone Number

**Emergency Number** : +1-866-562-4708 (ProPharma)

### SECTION 2: HAZARDS IDENTIFICATION

#### 2.1. Classification of the Substance or Mixture

##### GHS-US Classification

Serious eye damage/eye irritation, Category 2A H319

Respiratory sensitization, Category 1 H334

Skin sensitization, Category 1 H317

Combustible dust

#### 2.2. Label Elements

##### GHS-US Labeling

**Hazard Pictograms (GHS-US)** :



GHS08

**Signal Word (GHS-US)** :

Danger

**Hazard Statements (GHS-US)** :

May form combustible dust concentrations in air [if small particles are generated during further processing, handling or by other means.].

H317 - May cause an allergic skin reaction.

H319 - Causes serious eye irritation.

H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled.

**Precautionary Statements (GHS-US)** :

P261 - Avoid breathing dust.

P264 - Wash hands, forearms and face thoroughly after handling.

P272 - Contaminated work clothing must not be allowed out of the workplace.

P280 - Wear eye protection, protective gloves and clothing.

P284 - In case of inadequate ventilation wear respiratory protection.

P302+P352 - If on skin: Wash with plenty of soap and water.

P304+P340 - If inhaled: Remove person to fresh air and keep at rest in a position comfortable for breathing.

P305+P351+P338 - If in eyes: Rinse cautiously with water for several minutes.

Remove contact lenses, if present and easy to do. Continue rinsing.

P321 - Specific treatment (see Section 4 of this Safety Data Sheet on this label).

P333+P313 - If skin irritation or rash occurs: Get medical advice or attention.

P337+P313 - If eye irritation persists: Get medical advice or attention.

P342+P311 - If experiencing respiratory symptoms: Call a poison center or doctor.

P362+P364 - Take off contaminated clothing and wash it before reuse.

P501 - Dispose of contents and/or container to hazardous or special waste collection point, in accordance with local, regional, national and/or international regulations.

Keep away from heat, hot surfaces, sparks, open flames and other ignition sources.

# Ceftazidime for Injection, USP

## Safety Data Sheet

According to Federal Register / Vol. 89, No. 98 / Monday, May 20, 2024 / Rules and Regulations

No smoking. Proper grounding procedures to avoid static electricity should be followed. Prevent dust accumulation (to minimize explosion hazard). Avoid generating dust.

### 2.3 Hazards associated with known or reasonably anticipated uses

This product is a pharmaceutical product designed for administration to a patient by a qualified medical professional. No other uses are anticipated. A Process Hazard Analysis (PHA) or other hazard assessment for additional specific end uses should be performed to ensure that hazards are fully understood, and adequate safety measures are in place. See Section 10 for relevant reactivity and stability information.

### 2.4. Other Hazards

Exposure may aggravate pre-existing eye, skin, or respiratory conditions.

### 2.5. Unknown Acute Toxicity (GHS-US)

No data available

## SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

### 3.1. Substance

Not applicable

### 3.2. Mixture

Name	Synonyms	Product Identifier	%	GHS US classification
Ceftazidime hydrate	Ceftazidime pentahydrate / Pyridinium, 1-[[[(6R,7R)-7-[[[(2Z)-(2-amino-4-thiazolyl)[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, inner salt, hydrate (1:5) / (6R,7R)-7-((Z)-2-(2-Aminothiazol-4-yl)-2-[[[(2-carboxypropan-2-yl)oxy]imino]acetamido]-8-oxo-3-[[pyridin-1-ium-1-yl)methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate pentahydrate / ceftazidime / Ceftazidime	(CAS-No.) 78439-06-2	88 – 90	Resp. Sens. 1, H334 Skin Sens. 1, H317 Comb. Dust
Disodium carbonate	Sodium carbonate / Carbonic acid, disodium salt / Soda ash / Sodium carbonate (2:1) / Sodium carbonate, anhydrous / Carbonic acid sodium salt (1:2) / SODIUM CARBONATE / Sodium carbonate anhydrous	(CAS-No.) 497-19-8	10 – 12	Eye Irrit. 2A, H319

\* The actual concentration of ingredient(s) is withheld as a trade secret in accordance with the 29 CFR 1910.1200. Percentages are listed in weight by weight percentage (w/w%) for liquid and solid ingredients. Gas ingredients are listed in volume by volume percentage (v/v%). Full text of H-phrases: see section 16.

## SECTION 4: FIRST AID MEASURES

### 4.1. Description of First-aid Measures

**First-aid Measures General:** Never give anything by mouth to an unconscious person. If you feel unwell, seek medical advice (show the label where possible). If product is biologically contaminated, follow all institutional protocols concerning the potential release of pathogens.

**First-aid Measures After Inhalation:** Using proper respiratory protection, immediately move the exposed person to fresh air. Encourage exposed person to cough, spit out, and blow nose to remove dust. Obtain medical attention if breathing difficulty persists.

**First-aid Measures After Skin Contact:** Remove contaminated clothing. Wash affected area with soap and water for at least 15 minutes. Obtain medical attention if irritation/rash develops or persists.

**First-aid Measures After Eye Contact:** Remove contact lenses, if present and easy to do. Continue rinsing. Rinse cautiously with water for at least 15 minutes. Obtain medical attention.

**First-aid Measures After Ingestion:** Rinse mouth. Do NOT induce vomiting. Obtain medical attention.

### 4.2. Most Important Symptoms and Effects Both Acute and Delayed

**Symptoms/Injuries:** May cause allergy or asthma symptoms or breathing difficulties if inhaled. Skin sensitization. Causes serious eye irritation.

**Symptoms/Injuries After Inhalation:** Exposure may produce cough, mucous secretions, shortness of breath, chest tightness or other symptoms indicative of an allergic/sensitization reaction.

**Symptoms/Injuries After Skin Contact:** May cause an allergic skin reaction.

**Symptoms/Injuries After Eye Contact:** Causes serious eye irritation. Redness, pain, swelling, itching, burning, tearing, and blurred vision.

**Symptoms/Injuries After Ingestion:** Ingestion may cause adverse effects.

**Chronic Symptoms:** Inhalation may cause allergic respiratory reaction with asthma-like symptoms and difficulty breathing. Repeated and prolonged exposure may cause an allergic skin reaction.

### 4.3. Indication of Any Immediate Medical Attention and Special Treatment Needed

If exposed or concerned, get medical advice and attention. If medical advice is needed, have product container or label at hand. Treat needlestick exposures symptomatically to include monitoring for anaphylaxis.

# Ceftazidime for Injection, USP

Safety Data Sheet

According to Federal Register / Vol. 89, No. 98 / Monday, May 20, 2024 / Rules and Regulations

## SECTION 5: FIRE-FIGHTING MEASURES

### 5.1. Extinguishing Media

**Suitable Extinguishing Media:** Water spray, fog, carbon dioxide (CO<sub>2</sub>), alcohol-resistant foam, or dry chemical.

**Unsuitable Extinguishing Media:** Do not use a heavy water stream. Use of heavy stream of water may spread fire.

### 5.2. Special Hazards Arising From the Substance or Mixture

**Fire Hazard:** Not considered flammable but may burn at high temperatures. Product is not a dust as supplied; however, product dusts may be combustible.

**Explosion Hazard:** Product is not explosive. Product is not a dust as supplied; however, product dusts may be combustible.

**Reactivity:** Hazardous reactions will not occur under normal conditions.

### 5.3. Advice for Firefighters

**Precautionary Measures Fire:** Exercise caution when fighting any chemical fire.

**Firefighting Instructions:** Use water spray or fog for cooling exposed containers.

**Protection During Firefighting:** Do not enter fire area without proper protective equipment, including respiratory protection.

**Hazardous Combustion Products:** Oxides of carbon, nitrogen, sulfur and sodium.

**Other Information:** No additional information available.

## SECTION 6: ACCIDENTAL RELEASE MEASURES

### 6.1. Personal Precautions, Protective Equipment and Emergency Procedures

**General Measures:** Do not breathe dust. Do not get in eyes, on skin, or on clothing. If product is biologically contaminated, follow all institutional protocols concerning the potential release of pathogens.

#### 6.1.1. For Non-Emergency Personnel

**Protective Equipment:** Use appropriate personal protective equipment (PPE).

**Emergency Procedures:** Evacuate unnecessary personnel.

#### 6.1.2. For Emergency Personnel

**Protective Equipment:** Equip cleanup crew with proper protection.

**Emergency Procedures:** Eliminate ignition sources first, then ventilate the area. Upon arrival at the scene, a first responder is expected to recognize the presence of dangerous goods, protect oneself and the public, secure the area, and call for the assistance of trained personnel as soon as conditions permit.

### 6.2. Environmental Precautions

Prevent entry to sewers and public waters.

### 6.3. Methods and Materials for Containment and Cleaning Up

**For Containment:** Contain solid spills with appropriate barriers and prevent migration and entry into sewers or streams.

**Methods for Cleaning Up:** Clean up spills immediately and dispose of waste safely. Recover the product by vacuuming, shoveling or sweeping. Vacuum clean-up is preferred. If sweeping is required use water mist as a dust suppressant. Transfer spilled material to a suitable container for disposal. Contact competent authorities after a spill.

### 6.4. Reference to Other Sections

See Section 8 for exposure controls and personal protection and Section 13 for disposal considerations.

## SECTION 7: HANDLING AND STORAGE

### 7.1. Precautions for Safe Handling

**Additional Hazards When Processed:** Material may be biologically contaminated with pathogenic organisms during use.

**Precautions for Safe Handling:** Wash hands and other exposed areas with mild soap and water before eating, drinking or smoking and when leaving work. Avoid prolonged contact with eyes, skin and clothing. Avoid breathing dust. Contaminated sharps should be handled with care and discarded immediately or as soon as possible in containers that are closable, puncture-resistant, leak proof on sides and bottoms, and appropriately labeled. Contact your local health department for referral to a syringe disposal program. In hospital and workplace settings, contaminated sharps are to be handled in accordance with established protocols.

**Hygiene Measures:** Handle in accordance with good industrial hygiene and safety procedures.

### 7.2. Conditions for Safe Storage, Including Any Incompatibilities

**Technical Measures:** Comply with applicable regulations.

**Storage Conditions:** Keep container closed when not in use. Store in a dry, cool place. Keep/Store away from direct sunlight, extremely high or low temperatures and incompatible materials.

**Incompatible Materials:** Strong acids, strong bases, strong oxidizers.

**Storage Temperature:** Do not freeze reconstituted liquid!

### 7.3. Specific End Use(s)

Cephalosporin Antibiotic

# Ceftazidime for Injection, USP

Safety Data Sheet

According to Federal Register / Vol. 89, No. 98 / Monday, May 20, 2024 / Rules and Regulations

## SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

### 8.1. Control Parameters

For substances listed in section 3 that are not listed here, there are no established exposure limits from the manufacturer, supplier, importer, or the appropriate advisory agency including: ACGIH (TLV), AIHA (WEEL), NIOSH (REL), or OSHA (PEL).


### 8.2. Exposure Controls

#### Appropriate Engineering Controls

: Suitable eye/body wash equipment should be available in the vicinity of any potential exposure. Ensure adequate ventilation, especially in confined areas. Ensure all national/local regulations are observed.

#### Personal Protective Equipment

: Gloves. Protective clothing. Protective goggles or glasses. Insufficient ventilation: wear respiratory protection.



#### Materials for Protective Clothing

: Chemically resistant materials and fabrics.

#### Hand Protection

: Wear protective gloves.

#### Eye and Face Protection

: Chemical goggles or safety glasses.

#### Skin and Body Protection

: Wear suitable protective clothing.

#### Respiratory Protection

: If exposure limits are exceeded or irritation is experienced, approved respiratory protection should be worn. In case of inadequate ventilation, oxygen deficient atmosphere, or where exposure levels are not known wear approved respiratory protection.

#### Thermal Hazard Protection

: Not applicable.

#### Environmental Exposure Controls

: Avoid unnecessary release into the environment.

#### Other Information

: When using, do not eat, drink or smoke.

## SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

### 9.1. Information on Basic Physical and Chemical Properties

Physical State	: Solid
Color	: White to cream-colored crystalline powder
Odor	: No data available
pH	: 5 – 7.5 [10 % aqueous solution]
Melting Point	: No data available
Freezing Point	: No data available
Boiling Point	: No data available
Flash Point	: No data available
Auto-ignition Temperature	: No data available
Decomposition Temperature	: No data available
Flammability (solid, gas)	: No data available
Vapor Pressure	: No data available
Relative Vapor Density at 20°C	: No data available
Relative Density	: No data available
Solubility	: Water: Soluble
Partition Coefficient: N-Octanol/Water	: No data available
Viscosity, Kinematic	: No data available
Particle Size	: No data available
Particle Size Distribution	: No data available
Particle Shape	: No data available
Particle Aspect Ratio	: No data available
Particle Aggregation State	: No data available
Particle Agglomeration State	: No data available
Particle Specific Surface Area	: No data available
Particle Dustiness	: No data available

### 9.2. Other Information

No additional information available

# Ceftazidime for Injection, USP

Safety Data Sheet

According to Federal Register / Vol. 89, No. 98 / Monday, May 20, 2024 / Rules and Regulations

## SECTION 10: STABILITY AND REACTIVITY

### 10.1. Reactivity

Hazardous reactions will not occur under normal conditions.

### 10.2. Chemical Stability

Stable under recommended handling and storage conditions (see section 7).

### 10.3. Possibility of Hazardous Reactions, Including those Associated with Foreseeable Emergencies

Hazardous polymerization will not occur. Product is not a dust as supplied; however, product dusts may be combustible. Under fire conditions, thermal decomposition products include the following:

### 10.4. Conditions to Avoid

Direct sunlight, extremely high or low temperatures, and incompatible materials. Avoid creating or spreading dust.

### 10.5. Incompatible Materials

Strong acids, strong bases, strong oxidizers.

### 10.6. Hazardous Decomposition Products

Thermal decomposition may produce: Oxides of carbon, nitrogen, sulfur and sodium.

## SECTION 11: TOXICOLOGICAL INFORMATION

### 11.1. Information on Toxicological Effects

**Likely Routes of Exposure:** Dermal, Ingestion, Inhalation, Eye contact

**Acute Toxicity (Oral):** Not classified.

**Acute Toxicity (Dermal):** Not classified.

**Acute Toxicity (Inhalation):** Not classified.

Disodium carbonate (497-19-8)	
LD50 Oral Rat	2800 mg/kg
LD50 Dermal Rabbit	> 2000 mg/kg (No deaths)
LC50 Inhalation Rat	2300 mg/m <sup>3</sup> (Exposure time: 2 h)

**Skin Corrosion/Irritation:** Not classified.

**pH:** 5 – 7.5 [10 % aqueous solution]

**Serious Eye Damage/Irritation:** Causes serious eye irritation.

**pH:** 5 – 7.5 [10 % aqueous solution]

**Respiratory or Skin Sensitization:** May cause allergy or asthma symptoms or breathing difficulties if inhaled. May cause an allergic skin reaction.

**Germ Cell Mutagenicity:** Not classified.

**Carcinogenicity:** Not classified.

**Reproductive Toxicity:** Not classified.

**Specific Target Organ Toxicity (Single Exposure):** Not classified.

**Specific Target Organ Toxicity (Repeated Exposure):** Not classified.

**Aspiration Hazard:** Not classified.

**Symptoms/Injuries After Inhalation:** Exposure may produce cough, mucous secretions, shortness of breath, chest tightness or other symptoms indicative of an allergic/sensitization reaction.

**Symptoms/Injuries After Skin Contact:** May cause an allergic skin reaction.

**Symptoms/Injuries After Eye Contact:** Causes serious eye irritation. Redness, pain, swelling, itching, burning, tearing, and blurred vision.

**Symptoms/Injuries After Ingestion:** Ingestion may cause adverse effects.

**Chronic Symptoms:** Inhalation may cause allergic respiratory reaction with asthma-like symptoms and difficulty breathing. Repeated and prolonged exposure may cause an allergic skin reaction.

## SECTION 12: ECOLOGICAL INFORMATION

### 12.1. Toxicity

**Ecology - General** : Not classified.

Disodium carbonate (497-19-8)	
LC50 Fish 1	300 mg/l (Exposure time: 96 h - Species: Lepomis macrochirus [static] Source: EPA)
EC50 - Crustacea [1]	265 mg/l (Exposure time: 48 h - Species: Daphnia magna)
LC50 Fish 2	310 – 1220 mg/l (Exposure time: 96 h - Species: Pimephales promelas [static] Source: EPA)

# Ceftazidime for Injection, USP

Safety Data Sheet

According to Federal Register / Vol. 89, No. 98 / Monday, May 20, 2024 / Rules and Regulations

## 12.2. Persistence and Degradability

Ceftazidime for Injection, USP	
Persistence and Degradability	Expected to be biodegradable.

## 12.3. Bioaccumulative Potential

Ceftazidime for Injection, USP	
Bioaccumulative Potential	Not expected to bioaccumulate.
Disodium carbonate (497-19-8)	
BCF Fish 1	(no bioaccumulation)

## 12.4. Mobility in Soil

Ceftazidime for Injection, USP	
Ecology - Soil	Adsorption to solid soil phase is not expected. Leaches if exposed to water.

## 12.5. Other Adverse Effects

Other Adverse Effects : None known.  
Other Information : Avoid release to the environment.

## SECTION 13: DISPOSAL CONSIDERATIONS

### 13.1. Waste Treatment Methods

**Waste Treatment Methods:** Incineration is the preferred method for disposal of waste product.

**Sewage Disposal Recommendations:** Do not dispose of waste into sewer. Do not empty into drains.

**Waste Disposal Recommendations:** Dispose of contents/container in accordance with local, regional, national, and international regulations.

**Additional Information:** Biologically contaminated materials should be incinerated.

**Ecology - Waste Materials:** Avoid release to the environment.

## SECTION 14: TRANSPORT INFORMATION

The shipping description(s) stated herein were prepared in accordance with certain assumptions at the time the SDS was authored, and can vary based on a number of variables that may or may not have been known at the time the SDS was issued.

### 14.1. In Accordance with DOT

Not regulated for transport

### 14.2. In Accordance with IMDG

Not regulated for transport

### 14.3. In Accordance with IATA

Not regulated for transport

## SECTION 15: REGULATORY INFORMATION

### 15.1. US Federal Regulations

Ceftazidime for Injection, USP	
SARA Section 311/312 Hazard Classes	Health hazard - Respiratory or skin sensitization Health hazard - Serious eye damage or eye irritation Physical hazard - Combustible dust

Disodium carbonate (497-19-8)	
Listed on the United States TSCA (Toxic Substances Control Act) inventory - Status: Active	

### 15.2. US State Regulations

Neither this product nor its chemical components appear on any US state lists, or its chemical components are not required to be disclosed.

## SECTION 16: OTHER INFORMATION, INCLUDING DATE OF PREPARATION OR LAST REVISION

Date of Preparation or Latest Revision : 05/14/2025  
Other Information : This document has been prepared in accordance with the SDS requirements of the OSHA Hazard Communication Standard 29 CFR 1910.1200

### GHS Full Text Phrases:

H317	May cause an allergic skin reaction
H319	Causes serious eye irritation
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled

# Ceftazidime for Injection, USP

## Safety Data Sheet

According to Federal Register / Vol. 89, No. 98 / Monday, May 20, 2024 / Rules and Regulations

---

### Glossary of Data Source Abbreviations

ATSDR: Agency for Toxic Substances and Disease Registry (U.S. Department of Health and Human Services)

AU\_WES: Australia WES

CHEMVIEW: ChemView (U.S. Environmental Protection Agency)

EC\_RAR: European Commission Renewal Assessment Report

EC\_SCOEL: European Commission Scientific Committee on Occupational Exposure Limits

ECETOC: European Centre for Ecotoxicology and Toxicology of Chemicals Reports

ECHA\_API: European Chemicals Agency API

ECHA\_RAC: ECHA Committee for Risk Assessment

EFSA: European Food Safety Authority

EPA: U.S. Environmental Protection Agency

EPA\_AEGL: Acute Exposure Guideline Levels (U.S. Environmental Protection Agency)

EPA\_FIFRA: Federal Insecticide, Fungicide, and Rodenticide Act Reregistration Eligibility Decision (U.S. Environmental Protection Agency)

EPA\_HPVC: High Production Volume Chemicals (U.S. Environmental Protection Agency)

EPA\_TRED: Risk Assessment for Tolerance Reassessment Eligibility Decision (U.S. Environmental Protection Agency)

EU\_CLH: European Union Harmonised Classification and Labelling Proposal

EU\_RAR: European Union Risk Assessment Report

FOOD\_JOURN: Food Research Journal (1956)

IARC: The International Agency for Research on Cancer

IDLH: National Institute for Occupational Health and Safety Immediately Dangerous to Life or Health Value Profiles

IUCLID: International Uniform Chemical Information Database

JAPAN\_GHS: Japan GHS Basis for Classification Data

JP\_J-CHECK: Japan J-Check

KR\_NIER: South Korea National Institute of Environmental Research Evaluations

NICNAS: Australia National Industrial Chemicals Notification and Assessment Scheme

NIOSH: National Institute for Occupational Health and Safety (U.S. Department of Health and Human Services)

NLM\_CIP: National Library of Medicine ChemID plus database

NLM\_HSDB: National Library of Medicine Hazardous Substance Data Bank

NLM\_PUBMED: National Library of Medicine PubMed database

NTP: National Toxicology Program

NZ\_CCID: New Zealand Chemical Classification and Information Database

OECD\_EHSP: Environment, Health, and Safety Publication (Organisation for Economic Co-operation and Development)

OECD\_SIDS: Screening Information Data Sets (Organisation for Economic Co-operation and Development)

WHO: World Health Organization

*This information is based on our current knowledge and is intended to describe the product for the purposes of health, safety and environmental requirements only. It should not therefore be construed as guaranteeing any specific property of the product.*

SDS US (GHS HazCom)